Natera (NTRA) closed at $319.82 on November 11, 2026, up 2.5% from the previous close, on volume of 1,623,963 shares (30-day average 1,942,584).
Data as of November 11, 2026.
11-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 5, 2026 | 6 Leg Put Combo with Ratio | 20-Nov-26320 : 350[1.5x] : 360[3.5x] : 380[1.5x] : 390 : 410[1.5x] P | 1,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
Business Wire (Tue, 10-Nov 7:00 AM ET)
Cathie Wood's Ark Invest buys $96M of SpaceX, adds to Nvidia and AMD; trims Broadcom
Seeking Alpha News (Mon, 9-Nov 7:05 AM ET)
Market Chameleon (Fri, 6-Nov 4:55 AM ET)
Natera Announces Leadership Transition
Business Wire (Thu, 5-Nov 4:06 PM ET)
Natera Reports Third Quarter 2026 Financial Results
Business Wire (Thu, 5-Nov 4:05 PM ET)
Business Wire (Thu, 5-Nov 7:00 AM ET)
Business Wire (Wed, 4-Nov 7:00 AM ET)
Medicare Expands Coverage for Signatera MRD Test in Hepatocellular Carcinoma
Business Wire (Tue, 3-Nov 7:00 AM ET)
Natera to Report its Third Quarter Results on November 5, 2026
Business Wire (Thu, 29-Oct 8:00 AM ET)
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Natera trades on the NASDAQ stock market under the symbol NTRA.
As of November 11, 2026, NTRA stock price climbed to $319.82 with 1,623,963 million shares trading.
NTRA has a beta of 1.47, meaning it tends to be more sensitive to market movements. NTRA has a correlation of 0.11 to the broad based SPY ETF.
NTRA has a market cap of $46.38 billion. This is considered a Large Cap stock.
Last quarter Natera reported $794 million in Revenue and -$.42 earnings per share. This beat revenue expectation by $87 million and missed earnings estimates by -$.16.
In the last 3 years, NTRA traded as high as $437.41 and as low as $46.96.
The top ETF exchange traded funds that NTRA belongs to (by Net Assets): VTI, VB, VBK, VXF, IBB.
NTRA has outperformed the market in the last year with a return of +54.8%, while the SPY ETF gained +12.6%. In the last 3 month period, NTRA beat the market returning +0.5%, while SPY returned -1.5%. However, in the most recent 2 weeks NTRA has underperformed the stock market by returning -22.2%, while SPY returned -1.3%.
NTRA support price is $302.29 and resistance is $321.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NTRA shares will trade within this expected range on the day.
